Scientists have identified a protein that acts as a master switch for the deadly lung scarring seen in idiopathic pulmonary fibrosis, a discovery that could lead to the first treatments capable of reversing the disease. The finding offers new hope for patients who currently face a survival window of just two to five years after diagnosis.
In pulmonary fibrosis, the body’s normal wound healing process goes wrong. Instead of repairing damaged tissue, the lungs produce progressive scar tissue that makes breathing increasingly difficult. Only two drugs are approved for the most common form, idiopathic pulmonary fibrosis (IPF), and neither can reverse the scarring. The new study, published in Science Advances, identifies a protein called vitronectin as a key driver of this process. Researchers found that vitronectin acts as a signal that reprograms immune cells known as macrophages. Normally, macrophages help repair tissue after injury. But when exposed to vitronectin, they shift into a state that produces scarring instead of healing.
The research team used a novel 3D tissue culture system that mimics the fibrotic environment inside the lungs. This allowed them to observe, for the first time, how vitronectin changes the way macrophages produce energy, pushing them into an overactive scarring state. “This is a completely new mechanism to understand how fibrosis happens,” the researchers said. Crucially, what the team saw in the 3D cultures was confirmed in animal models and in tissue samples from patients with IPF, validating the finding as relevant to human disease.
What This Means for Patients
For the roughly 100,000 Americans living with IPF, the discovery represents a potential turning point. Current treatments only slow disease progression. By targeting the vitronectin-macrophage pathway, scientists believe they can develop drugs that stop or even reverse the scarring process. The next step is to identify compounds that can effectively inhibit vitronectin in the lungs.
“Understanding this mechanism is critical to identifying new therapeutic agents for fibrosis patients,” said Associate Professor Gang Liu, co-first author of the study. “Now we can work to identify new drugs that can most effectively inhibit vitronectin so we can translate this research into clinical practice and help find a new cure for this debilitating disease.” With a defined molecular target now in hand, the research team is optimistic that clinical trials could begin within the next several years, offering a path toward a cure where none currently exists.